Greenstone Biosciences received NIH funding to develop drug candidates targeting myocardial fibrosis in Duchenne muscular dystrophy, a genetic disorder where cardiac scarring is the leading cause of death. The program combines patient-derived disease models, proteomics, and AI-driven screening to identify therapeutics for patients who fail or cannot tolerate current corticosteroid treatment.
Key Points
- Over 25% of DMD patients fail or cannot tolerate corticosteroid therapy
- No approved drug directly targets disease-related cardiac scarring in DMD
- Platform uses patient stem cells, proteomics, and generative AI for candidate discovery
Longevity Analysis
Cardiac fibrosis in DMD represents a pathological state where the heart's structural integrity deteriorates due to excessive collagen deposition, ultimately compromising circulation and oxygen delivery. The approach—using patient-derived models and unbiased proteomics—addresses a critical gap: standard models miss the molecular signatures that distinguish responders from non-responders to existing therapy. By identifying the specific biochemical drivers of scarring in individual patients, this work moves beyond symptomatic management toward mechanism-based prevention of organ failure, extending both lifespan and healthspan in a population where current options are severely limited.
Original published by LT Wire.